KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Profit After Tax: 2009-2024

Historic Profit After Tax for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$2.0 billion.

  • Teva Pharmaceutical Industries' Profit After Tax rose 199.31% to $434.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $662.0 million, marking a year-over-year increase of 152.41%. This contributed to the annual value of -$2.0 billion for FY2024, which is 218.54% down from last year.
  • According to the latest figures from FY2024, Teva Pharmaceutical Industries' Profit After Tax is -$2.0 billion, which was down 218.54% from -$615.0 million recorded in FY2023.
  • Teva Pharmaceutical Industries' Profit After Tax's 5-year high stood at $456.0 million during FY2021, with a 5-year trough of -$4.1 billion in FY2020.
  • Moreover, its 3-year median value for Profit After Tax was -$2.0 billion (2024), whereas its average is -$1.7 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Profit After Tax spiked by 111.12% in 2021, and later tumbled by 648.03% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' Profit After Tax (Yearly) stood at -$4.1 billion in 2020, then skyrocketed by 111.12% to $456.0 million in 2021, then tumbled by 648.03% to -$2.5 billion in 2022, then spiked by 75.39% to -$615.0 million in 2023, then plummeted by 218.54% to -$2.0 billion in 2024.